Clinical Research Directory
Browse clinical research sites, groups, and studies.
Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)
Sponsor: University of Pennsylvania
Summary
This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.
Official title: Phase IV Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2022-02-07
Completion Date
2025-05-30
Last Updated
2026-10-30
Healthy Volunteers
No
Conditions
Interventions
Secukinumab Auto-Injector
300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)
Locations (1)
Hospital at the University of Pennsylvania
Philadelphia, Pennsylvania, United States